

**Clinical trial results:****A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Women****Summary**

EudraCT number	2012-003708-11
Trial protocol	BE GB PT IT FR
Global end of trial date	06 September 2018

Results information

Result version number	v1 (current)
This version publication date	22 September 2019
First version publication date	22 September 2019

Trial information**Trial identification**

Sponsor protocol code	GS-US-236-0128
-----------------------	----------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01705574
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Gilead Sciences
Sponsor organisation address	333 Lakeside Drive, Foster City, CA, United States, 94404
Public contact	Gilead Clinical Study Information Center, Gilead Sciences, GileadClinicalTrials@gilead.com
Scientific contact	Gilead Clinical Study Information Center, Gilead Sciences, GileadClinicalTrials@gilead.com
Sponsor organisation name	Gilead Sciences
Sponsor organisation address	333 Lakeside Drive, Foster City, CA, United States, 94404
Public contact	Gilead Clinical Study Information Center, Gilead Sciences, GileadClinicalTrials@gilead.com
Scientific contact	Gilead Clinical Study Information Center, Gilead Sciences, GileadClinicalTrials@gilead.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No	No

1901/2006 apply to this trial?	
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	06 September 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	09 February 2015
Global end of trial reached?	Yes
Global end of trial date	06 September 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study was to evaluate the efficacy of a regimen containing Stribild® (STB; elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; E/C/F/TDF) fixed-dose combination (FDC) versus ritonavir (RTV)-boosted atazanavir (ATV/r) plus Truvada® (TVD; emtricitabine/tenofovir disoproxil fumarate; FTC/TDF) in HIV-1 infected, antiretroviral treatment-naïve adult women.

Protection of trial subjects:

The protocol and consent/assent forms were submitted by each investigator to a duly constituted Independent Ethics Committee (IEC) or Institutional Review Board (IRB) for review and approval before study initiation. All revisions to the consent/assent forms (if applicable) after initial IEC/IRB approval were submitted by the investigator to the IEC/IRB for review and approval before implementation in accordance with regulatory requirements.

This study was conducted in accordance with recognized international scientific and ethical standards, including but not limited to the International Conference on Harmonization guideline for Good Clinical Practice (ICH GCP) and the original principles embodied in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	24 October 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Portugal: 21
Country: Number of subjects enrolled	United Kingdom: 20
Country: Number of subjects enrolled	Puerto Rico: 3
Country: Number of subjects enrolled	Russian Federation: 194
Country: Number of subjects enrolled	Thailand: 24
Country: Number of subjects enrolled	Uganda: 163
Country: Number of subjects enrolled	Dominican Republic: 20
Country: Number of subjects enrolled	United States: 118
Country: Number of subjects enrolled	Mexico: 5

Country: Number of subjects enrolled	Belgium: 8
Country: Number of subjects enrolled	France: 2
Country: Number of subjects enrolled	Italy: 5
Worldwide total number of subjects	583
EEA total number of subjects	56

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	582
From 65 to 84 years	1
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants were enrolled at study sites in North America, Europe, Dominican Republic, Thailand, and Uganda. The first participant was screened on 24 October 2012. The last study visit occurred on 06 September 2018.

Pre-assignment

Screening details:

810 participants were screened.

Period 1

Period 1 title	Double-Blind Phase
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Double-Blind STB

Arm description:

Double-Blind (DB) Phase : STB 150/150/200/300 mg FDC + ATV placebo + RTV placebo + TVD placebo orally once daily with food for 48 weeks

Arm type	Experimental
Investigational medicinal product name	Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Investigational medicinal product code	
Other name	Stribild® ; STB; E/C/F/TDF
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

150/150/200/300 mg FDC administered orally once daily with food

Investigational medicinal product name	Atazanavir placebo
Investigational medicinal product code	
Other name	ATV placebo
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Capsule orally once daily with food

Investigational medicinal product name	Ritonavir placebo
Investigational medicinal product code	
Other name	RTV placebo
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Tablet orally once daily with food

Investigational medicinal product name	Emtricitabine/tenofovir disoproxil fumarate placebo
Investigational medicinal product code	
Other name	FTC/TDF placebo; TVD placebo
Pharmaceutical forms	Tablet

Routes of administration	Oral use
--------------------------	----------

Dosage and administration details:

Tablet administered orally once daily with food

Arm title	Double-Blind ATV+RTV+TVD
------------------	--------------------------

Arm description:

Double-Blind Phase: ATV 300 mg + RTV 100 mg + TVD 200/300 mg FDC + STB placebo orally once daily with food for 48 weeks

Arm type	Experimental
Investigational medicinal product name	Atazanavir
Investigational medicinal product code	
Other name	Reyataz®; ATV
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

300 mg capsule administered orally once daily with food

Investigational medicinal product name	Ritonavir
Investigational medicinal product code	
Other name	RTV; Norvir®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

100 mg tablet orally once daily with food

Investigational medicinal product name	Emtricitabine/tenofovir disoproxil fumarate
Investigational medicinal product code	
Other name	FTC/TDF; Truvada®; TVD
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

200/300 mg FDC tablet administered orally once daily with food

Investigational medicinal product name	Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate placebo
Investigational medicinal product code	
Other name	E/C/F/TDF placebo; STB placebo
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Tablet orally once daily with food

Number of subjects in period 1^[1]	Double-Blind STB	Double-Blind ATV+RTV+TVD
Started	289	286
Completed	260	249
Not completed	29	37
Withdrew Consent	8	5
Non-Compliance with Study Drug	4	5

Adverse Event	3	10
Pregnancy	1	1
Protocol Violation	1	-
Lost to follow-up	12	16

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 4 participants in each arm who were randomized but not treated are not included in the subject disposition table.

Period 2

Period 2 title	Open-Label Extension (OLE) Phase
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Double-Blind STB to Open-Label STB

Arm description:

Open-Label Extension Phase: After 48 weeks of blinded treatment participants continued on the blinded treatment for 12 weeks and returned for an unblinding visit at Week 60. Participants who were virologically suppressed at Week 48 during the double-blind phase had the option to receive open-label STB FDC orally once daily with food for 48 weeks.

Arm type	Experimental
Investigational medicinal product name	Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Investigational medicinal product code	
Other name	Stribild® ; STB; E/C/F/TDF
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

150/150/200/300 mg FDC administered orally once daily with food

Arm title	Double-Blind ATV+RTV +TVD to Open-Label GEN
------------------	---

Arm description:

Open-Label Extension Phase: After 48 weeks of blinded treatment participants continued on the blinded treatment for 12 weeks and returned for an unblinding visit at Week 60. Participants who were virologically suppressed at Week 48 during the double-blind phase had the option to be re-randomized and receive open-label Genvoya® (GEN; elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; E/C/F/TAF) 150/150/200/10 mg FDC orally once daily with food for 48 weeks.

Arm type	Experimental
Investigational medicinal product name	Elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide
Investigational medicinal product code	
Other name	Genvoya®; GEN; E/C/F/TAF
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

150/150/200/10 mg FDC orally once daily with food

Arm title	Double-Blind ATV+RTV+TVD to Open-Label ATV+RTV+TVD
------------------	--

Arm description:

Open-Label Extension Phase: After 48 weeks of blinded treatment participants continued on the blinded treatment for 12 weeks and returned for an unblinding visit at Week 60. Participants who were

virologically suppressed at Week 48 during the double-blind phase had the option to be re-randomized and receive open-label ATV 300 mg + RTV 100 mg + TVD 200/300 mg FDC orally once daily with food for 48 weeks.

Arm type	Experimental
Investigational medicinal product name	Atazanavir
Investigational medicinal product code	
Other name	Reyataz®; ATV
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

300 mg capsule orally with food once daily

Investigational medicinal product name	Ritonavir
Investigational medicinal product code	
Other name	Norvir®; RTV
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

100 mg tablet orally with food once daily

Investigational medicinal product name	Emtricitabine/tenofovir disoproxil fumarate
Investigational medicinal product code	
Other name	FTC/TDF; Truvada®; TVD
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

200/300 mg FDC tablet orally with food once daily

Number of subjects in period 2 ^[2]	Double-Blind STB to Open-Label STB	Double-Blind ATV+RTV +TVD to Open-Label GEN	Double-Blind ATV+RTV+TVD to Open-Label ATV+RTV+TVD
Started	246	159	53
Completed	231	148	48
Not completed	15	11	5
Withdrew Consent	4	4	1
Non- Compliance with Study Drug	-	1	-
Physician decision	-	2	-
Adverse Event	3	-	1
Death	2	1	-
Pregnancy	-	1	1
Lost to follow-up	6	2	2

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: [1] Double-Blind STB to Open-Label STB arm: 14 participants did not enter the OLE STB arm.

[2] Double-Blind ATV+RTV +TVD to Open-Label GEN: 159 participants entered from the DB ATV+RTV+TVD arm.

[3] Double-Blind ATV+RTV+TVD to Open-Label ATV+RTV+TVD: 53 participants entered from the DB

ATV+ RTV + TVD arm.

Baseline characteristics

Reporting groups

Reporting group title	Double-Blind STB
-----------------------	------------------

Reporting group description:

Double-Blind (DB) Phase : STB 150/150/200/300 mg FDC + ATV placebo + RTV placebo + TVD placebo orally once daily with food for 48 weeks

Reporting group title	Double-Blind ATV+RTV+TVD
-----------------------	--------------------------

Reporting group description:

Double-Blind Phase: ATV 300 mg + RTV 100 mg + TVD 200/300 mg FDC + STB placebo orally once daily with food for 48 weeks

Reporting group values	Double-Blind STB	Double-Blind ATV+RTV+TVD	Total
Number of subjects	289	286	575
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	36 ± 10.1	36 ± 9.7	-
Gender categorical Units: Subjects			
Female	289	286	575
Male	0	0	0
Race Units: Subjects			
Asian	9	17	26
Black	143	133	276
Native Hawaiian or Pacific Islander	0	1	1
White	128	119	247
Other	9	15	24
Not Permitted	0	1	1
Ethnicity Units: Subjects			
Hispanic or Latino	20	24	44
Not Hispanic or Latino	269	262	531
Not Permitted	0	0	0
HIV-1 RNA Category Units: Subjects			
≤ 100,000 copies/mL	220	214	434
> 100,000 to ≤400,000 copies/mL	44	50	94
> 400,000 copies/mL	25	22	47
CD4 Cell Count Units: cells/μL arithmetic mean standard deviation	376 ± 199.6	385 ± 210.2	-

End points

End points reporting groups

Reporting group title	Double-Blind STB
Reporting group description: Double-Blind (DB) Phase : STB 150/150/200/300 mg FDC + ATV placebo + RTV placebo + TVD placebo orally once daily with food for 48 weeks	
Reporting group title	Double-Blind ATV+RTV+TVD
Reporting group description: Double-Blind Phase: ATV 300 mg + RTV 100 mg + TVD 200/300 mg FDC + STB placebo orally once daily with food for 48 weeks	
Reporting group title	Double-Blind STB to Open-Label STB
Reporting group description: Open-Label Extension Phase: After 48 weeks of blinded treatment participants continued on the blinded treatment for 12 weeks and returned for an unblinding visit at Week 60. Participants who were virologically suppressed at Week 48 during the double-blind phase had the option to receive open-label STB FDC orally once daily with food for 48 weeks.	
Reporting group title	Double-Blind ATV+RTV +TVD to Open-Label GEN
Reporting group description: Open-Label Extension Phase: After 48 weeks of blinded treatment participants continued on the blinded treatment for 12 weeks and returned for an unblinding visit at Week 60. Participants who were virologically suppressed at Week 48 during the double-blind phase had the option to be re-randomized and receive open-label Genvoya® (GEN; elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; E/C/F/TAF) 150/150/200/10 mg FDC orally once daily with food for 48 weeks.	
Reporting group title	Double-Blind ATV+RTV+TVD to Open-Label ATV+RTV+TVD
Reporting group description: Open-Label Extension Phase: After 48 weeks of blinded treatment participants continued on the blinded treatment for 12 weeks and returned for an unblinding visit at Week 60. Participants who were virologically suppressed at Week 48 during the double-blind phase had the option to be re-randomized and receive open-label ATV 300 mg + RTV 100 mg + TVD 200/300 mg FDC orally once daily with food for 48 weeks.	
Subject analysis set title	ALL STB
Subject analysis set type	Intention-to-treat
Subject analysis set description: ITT Analysis Set included participants who were randomized into the study and received at least 1 dose of STB.	

Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 of the Double-Blind Phase as Determined by the US FDA-Defined Snapshot Algorithm

End point title	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 of the Double-Blind Phase as Determined by the US FDA-Defined Snapshot Algorithm
End point description: The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 of the double-blind phase was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Participants in the Intent-to-Treat (ITT) Analysis Set (randomized and received at least one dose of study drug) were analyzed.	
End point type	Primary
End point timeframe: Week 48	

End point values	Double-Blind STB	Double-Blind ATV+RTV+TVD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	289	286		
Units: Years				
number (not applicable)	87.2	80.8		

Statistical analyses

Statistical analysis title	HIV-1 RNA < 50 copies/mL– DB STB vs DB ATV+RTV+TVD
Statistical analysis description:	
The null hypothesis for non-inferiority was that the STB group was at least 12% worse than the ATV+RTV+TVD group with respect to the percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 (response rate as defined by the snapshot analysis algorithm). The alternative hypothesis was that the STB group was less than 12% worse than the ATV+RTV+TVD group	
Comparison groups	Double-Blind STB v Double-Blind ATV+RTV+TVD
Number of subjects included in analysis	575
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[1]
Parameter estimate	Difference in proportions
Point estimate	6.5
Confidence interval	
level	95.2 %
sides	2-sided
lower limit	0.4
upper limit	12.6

Notes:

[1] - Difference in percentages of virologic success and its 95.2% confidence interval (CI) were calculated based on baseline HIV-1 RNA and race stratum-adjusted Mantel-Haenszel (MH) proportion.

Statistical analysis title	HIV-1 RNA < 50 copies/mL - DB STB, DB ATV+RTV+TVD
Comparison groups	Double-Blind STB v Double-Blind ATV+RTV+TVD
Number of subjects included in analysis	575
Analysis specification	Pre-specified
Analysis type	superiority ^[2]
P-value	= 0.034 ^[3]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in proportions
Point estimate	6.5
Confidence interval	
level	95.2 %
sides	2-sided
lower limit	0.4
upper limit	12.6

Notes:

[2] - If non-inferiority of STB versus ATV+RTV+TVD was established, the same 95.2% CI used in evaluating noninferiority was used to evaluate superiority. The baseline HIV-1 RNA and race stratum-stratified, 2-sided CMH test was also used to assess

superiority as a secondary assessment.

[3] - P-value comparing virologic success was from the CMH test stratified by baseline HIV-1 RNA and race strata.

Secondary: Change From Baseline in CD4+ Cell Count at Week 48 of the Double-Blind Phase

End point title	Change From Baseline in CD4+ Cell Count at Week 48 of the Double-Blind Phase
-----------------	--

End point description:

Participants in the ITT Analysis Set with available data on-treatment were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline; Week 48

End point values	Double-Blind STB	Double-Blind ATV+RTV+TVD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	263	243		
Units: cells/ μ L				
arithmetic mean (standard deviation)	221 (\pm 165.1)	212 (\pm 176.8)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 for the STB group as Determined by the US FDA-Defined Snapshot Algorithm

End point title	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 for the STB group as Determined by the US FDA-Defined Snapshot Algorithm
-----------------	--

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Participants in the ITT Analysis Set who received STB through 96 weeks were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 96

End point values	ALL STB			
Subject group type	Subject analysis set			
Number of subjects analysed	278			
Units: Percentage of participants				
number (confidence interval 95%)	84.5 (79.7 to 88.6)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Receiving GEN or ATV+RTV+TVD With HIV-1 RNA < 50 Copies/mL at Week 48 of the Open-Label Extension Phase

End point title	Percentage of Participants Receiving GEN or ATV+RTV+TVD With HIV-1 RNA < 50 Copies/mL at Week 48 of the Open-Label Extension Phase
-----------------	--

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 of the open-label phase was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Participants in the OLE ITT Analysis Set were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Open-Label Extension Week 48

End point values	Double-Blind ATV+RTV +TVD to Open- Label GEN	Double-Blind ATV+RTV+TVD to Open-Label ATV+RTV+TVD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	159	53		
Units: Percentage of participants				
number (not applicable)	94.3	86.8		

Statistical analyses

No statistical analyses for this end point

Secondary: Change in CD4+ Cell Count at Week 48 of the Open-Label Extension Phase

End point title	Change in CD4+ Cell Count at Week 48 of the Open-Label Extension Phase
-----------------	--

End point description:

Participants in the OLE ITT Analysis Set with available data on-treatment were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline; Open-Label Extension Week 48

End point values	Double-Blind STB to Open- Label STB	Double-Blind ATV+RTV +TVD to Open- Label GEN	Double-Blind ATV+RTV+TVD to Open-Label ATV+RTV+TVD	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	239	151	49	
Units: cells/uL				
arithmetic mean (standard deviation)	265 (± 190.4)	35 (± 137.5)	49 (± 204.8)	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

First dose date up to the last dose date plus 30 days including DB phase and OLE phase (maximum duration: ALL STB = 239.9 weeks; DB ATV+RTV+TVD = 90.6 weeks; DB ATV+ RTV+TVD to OL GEN = 191.3 weeks ; DB ATV+RTV+TVD to OL ATV+RTV+TVD = 102.0 weeks)

Adverse event reporting additional description:

Adverse events reported included randomized participants who received at least 1 dose of any drug in either DB phase or OLE phase.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.0
--------------------	------

Reporting groups

Reporting group title	Double-Blind: STB
-----------------------	-------------------

Reporting group description:

Double-Blind Phase: STB 150/150/200/300 mg FDC + ATV placebo + RTV placebo + TVD placebo orally once daily with food for 48 weeks

Reporting group title	Double-Blind: ATV +RTV+TVD
-----------------------	----------------------------

Reporting group description:

Double-Blind Phase: ATV 300 mg + RTV 100 mg + TVD (200/300 mg) FDC + STB placebo orally once daily with food for 48 weeks

Reporting group title	DB STB to OL STB
-----------------------	------------------

Reporting group description:

Open-Label Extension Phase: After 48 weeks of blinded treatment participants continued on the blinded treatment for 12 weeks and returned for an unblinding visit at Week 60. Participants who were virologically suppressed at Week 48 during the double-blind phase had the option to receive open-label (OL) STB FDC orally once daily with food for 48 weeks.

Reporting group title	DB ATV+RTV+TVD to OL GEN
-----------------------	--------------------------

Reporting group description:

Open-Label Extension Phase: After 48 weeks of blinded treatment participants continued on the blinded treatment for 12 weeks and returned for an unblinding visit at Week 60. Participants who were virologically suppressed at Week 48 during the double-blind phase had the option to be re-randomized and receive open-label GEN 150/150/200/10 mg FDC orally once daily with food for 48 weeks.

Reporting group title	DB ATV+RTV+TVD to OL ATV+RTV+TVD
-----------------------	----------------------------------

Reporting group description:

Open-Label Extension Phase: After 48 weeks of blinded treatment participants continued on the blinded treatment for 12 weeks and returned for an unblinding visit at Week 60. Participants who were virologically suppressed at Week 48 during the double-blind phase had the option to be re-randomized and receive open-label ATV 300 mg + RTV 100 mg + TVD (200/300 mg) FDC orally once daily with food for 48 weeks.

Serious adverse events	Double-Blind: STB	Double-Blind: ATV +RTV+TVD	DB STB to OL STB
Total subjects affected by serious adverse events			
subjects affected / exposed	25 / 289 (8.65%)	29 / 286 (10.14%)	13 / 246 (5.28%)
number of deaths (all causes)	0	0	2
number of deaths resulting from adverse events			

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cervix carcinoma			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	1 / 246 (0.41%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Fibroadenoma of breast			
subjects affected / exposed	0 / 289 (0.00%)	0 / 286 (0.00%)	1 / 246 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroid cancer			
subjects affected / exposed	0 / 289 (0.00%)	0 / 286 (0.00%)	1 / 246 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine leiomyoma			
subjects affected / exposed	0 / 289 (0.00%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 289 (0.00%)	0 / 286 (0.00%)	1 / 246 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	2 / 289 (0.69%)	2 / 286 (0.70%)	1 / 246 (0.41%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ectopic pregnancy			

subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gestational hypertension			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Imminent abortion			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ruptured ectopic pregnancy			
subjects affected / exposed	0 / 289 (0.00%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine hypertonus			
subjects affected / exposed	0 / 289 (0.00%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 289 (0.00%)	0 / 286 (0.00%)	1 / 246 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 289 (0.00%)	0 / 286 (0.00%)	1 / 246 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Malaise			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			

Vaginal haemorrhage			
subjects affected / exposed	1 / 289 (0.35%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical dysplasia			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cyst			
subjects affected / exposed	0 / 289 (0.00%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine haemorrhage			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	2 / 289 (0.69%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neonatal respiratory distress			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleurisy			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Depression			
subjects affected / exposed	2 / 289 (0.69%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Confusional state			
subjects affected / exposed	0 / 289 (0.00%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Conversion disorder			
subjects affected / exposed	0 / 289 (0.00%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression suicidal			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Major depression			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stress			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Substance abuse			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			

Electrocardiogram T wave inversion			
subjects affected / exposed	0 / 289 (0.00%)	0 / 286 (0.00%)	1 / 246 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 289 (0.00%)	0 / 286 (0.00%)	1 / 246 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiomegaly			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery occlusion			
subjects affected / exposed	0 / 289 (0.00%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Dizziness			

subjects affected / exposed	0 / 289 (0.00%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	1 / 246 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic anaemia			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency anaemia			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Chalazion			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	1 / 246 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 289 (0.00%)	0 / 286 (0.00%)	1 / 246 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastritis			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 289 (0.00%)	0 / 286 (0.00%)	1 / 246 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 289 (0.00%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic hepatitis			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug-induced liver injury			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			

Stevens-Johnson syndrome			
subjects affected / exposed	1 / 289 (0.35%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema multiforme			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 289 (0.00%)	2 / 286 (0.70%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Musculoskeletal pain			
subjects affected / exposed	0 / 289 (0.00%)	2 / 286 (0.70%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal chest pain			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations Pneumonia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 289 (0.69%) 0 / 2 0 / 0	1 / 286 (0.35%) 0 / 1 0 / 0	1 / 246 (0.41%) 0 / 1 0 / 0
Gastroenteritis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 289 (0.35%) 0 / 1 0 / 0	0 / 286 (0.00%) 0 / 0 0 / 0	1 / 246 (0.41%) 0 / 1 0 / 0
Peritonitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 289 (0.35%) 0 / 1 0 / 0	1 / 286 (0.35%) 0 / 1 0 / 0	0 / 246 (0.00%) 0 / 0 0 / 0
Arthritis bacterial subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 289 (0.35%) 0 / 1 0 / 0	0 / 286 (0.00%) 0 / 0 0 / 0	0 / 246 (0.00%) 0 / 0 0 / 0
Bone tuberculosis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 289 (0.00%) 0 / 0 0 / 0	0 / 286 (0.00%) 0 / 0 0 / 0	1 / 246 (0.41%) 0 / 1 0 / 0
Breast abscess subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 289 (0.00%) 0 / 0 0 / 0	0 / 286 (0.00%) 0 / 0 0 / 0	1 / 246 (0.41%) 0 / 1 0 / 0
Catheter site infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 289 (0.35%) 0 / 1 0 / 0	0 / 286 (0.00%) 0 / 0 0 / 0	0 / 246 (0.00%) 0 / 0 0 / 0
Cellulitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 289 (0.00%) 0 / 0 0 / 0	1 / 286 (0.35%) 0 / 1 0 / 0	0 / 246 (0.00%) 0 / 0 0 / 0
Furuncle			

subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaria			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ophthalmic herpes zoster			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic inflammatory disease			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary tuberculosis			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syphilis			
subjects affected / exposed	0 / 289 (0.00%)	1 / 286 (0.35%)	0 / 246 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			

subjects affected / exposed	1 / 289 (0.35%)	0 / 286 (0.00%)	1 / 246 (0.41%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	DB ATV+RTV+TVD to OL GEN	DB ATV+RTV+TVD to OL ATV+RTV+TVD	
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 159 (7.55%)	4 / 53 (7.55%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cervix carcinoma			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibroadenoma of breast			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid cancer			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine leiomyoma			
subjects affected / exposed	1 / 159 (0.63%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			

subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	3 / 159 (1.89%)	2 / 53 (3.77%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ectopic pregnancy			
subjects affected / exposed	0 / 159 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gestational hypertension			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Imminent abortion			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ruptured ectopic pregnancy			
subjects affected / exposed	0 / 159 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine hypertonus			
subjects affected / exposed	1 / 159 (0.63%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 159 (0.63%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Death			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Vaginal haemorrhage			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical dysplasia			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cyst			
subjects affected / exposed	1 / 159 (0.63%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine haemorrhage			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neonatal respiratory distress			

subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleurisy			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Confusional state			
subjects affected / exposed	1 / 159 (0.63%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Conversion disorder			
subjects affected / exposed	1 / 159 (0.63%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression suicidal			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Major depression			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Substance abuse			

subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicidal ideation			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Electrocardiogram T wave inversion			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Cardiomegaly			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery occlusion			
subjects affected / exposed	1 / 159 (0.63%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 159 (0.63%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic anaemia			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency anaemia			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Chalazion			

subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 159 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	1 / 159 (0.63%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			

subjects affected / exposed	1 / 159 (0.63%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic hepatitis			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug-induced liver injury			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Stevens-Johnson syndrome			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erythema multiforme			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Musculoskeletal pain			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthralgia			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Arthritis			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis bacterial			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone tuberculosis			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast abscess			

subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Catheter site infection			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Furuncle			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaria			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ophthalmic herpes zoster			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic inflammatory disease			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary tuberculosis			

subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous abscess			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syphilis			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 159 (0.00%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Double-Blind: STB	Double-Blind: ATV +RTV+TVD	DB STB to OL STB
Total subjects affected by non-serious adverse events			
subjects affected / exposed	176 / 289 (60.90%)	194 / 286 (67.83%)	118 / 246 (47.97%)
Nervous system disorders			
Headache			
subjects affected / exposed	49 / 289 (16.96%)	44 / 286 (15.38%)	27 / 246 (10.98%)
occurrences (all)	56	58	36
Neuropathy peripheral			
subjects affected / exposed	21 / 289 (7.27%)	20 / 286 (6.99%)	12 / 246 (4.88%)
occurrences (all)	27	24	12
Dizziness			
subjects affected / exposed	17 / 289 (5.88%)	10 / 286 (3.50%)	7 / 246 (2.85%)
occurrences (all)	18	10	9
Blood and lymphatic system disorders			
Anaemia			

subjects affected / exposed occurrences (all)	11 / 289 (3.81%) 12	14 / 286 (4.90%) 15	18 / 246 (7.32%) 20
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	8 / 289 (2.77%) 9	15 / 286 (5.24%) 16	2 / 246 (0.81%) 2
Gastrointestinal disorders Nausea subjects affected / exposed occurrences (all)	43 / 289 (14.88%) 51	41 / 286 (14.34%) 46	6 / 246 (2.44%) 6
Vomiting subjects affected / exposed occurrences (all)	28 / 289 (9.69%) 33	17 / 286 (5.94%) 18	3 / 246 (1.22%) 4
Diarrhoea subjects affected / exposed occurrences (all)	15 / 289 (5.19%) 20	19 / 286 (6.64%) 20	6 / 246 (2.44%) 7
Dyspepsia subjects affected / exposed occurrences (all)	13 / 289 (4.50%) 15	15 / 286 (5.24%) 15	4 / 246 (1.63%) 4
Abdominal pain subjects affected / exposed occurrences (all)	17 / 289 (5.88%) 20	9 / 286 (3.15%) 9	1 / 246 (0.41%) 1
Hepatobiliary disorders Ocular icterus subjects affected / exposed occurrences (all)	1 / 289 (0.35%) 1	34 / 286 (11.89%) 36	0 / 246 (0.00%) 0
Jaundice subjects affected / exposed occurrences (all)	1 / 289 (0.35%) 1	30 / 286 (10.49%) 34	0 / 246 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	20 / 289 (6.92%) 25	18 / 286 (6.29%) 22	12 / 246 (4.88%) 13
Musculoskeletal and connective tissue disorders			

Back pain subjects affected / exposed occurrences (all)	20 / 289 (6.92%) 24	17 / 286 (5.94%) 19	13 / 246 (5.28%) 14
Arthralgia subjects affected / exposed occurrences (all)	10 / 289 (3.46%) 13	21 / 286 (7.34%) 24	9 / 246 (3.66%) 10
Infections and infestations			
Upper respiratory tract infection subjects affected / exposed occurrences (all)	50 / 289 (17.30%) 81	45 / 286 (15.73%) 64	36 / 246 (14.63%) 60
Malaria subjects affected / exposed occurrences (all)	34 / 289 (11.76%) 45	25 / 286 (8.74%) 31	14 / 246 (5.69%) 18
Urinary tract infection subjects affected / exposed occurrences (all)	22 / 289 (7.61%) 25	23 / 286 (8.04%) 23	15 / 246 (6.10%) 18
Influenza subjects affected / exposed occurrences (all)	20 / 289 (6.92%) 24	20 / 286 (6.99%) 25	14 / 246 (5.69%) 15
Vulvovaginal candidiasis subjects affected / exposed occurrences (all)	21 / 289 (7.27%) 27	20 / 286 (6.99%) 25	15 / 246 (6.10%) 17
Nasopharyngitis subjects affected / exposed occurrences (all)	15 / 289 (5.19%) 22	14 / 286 (4.90%) 21	8 / 246 (3.25%) 15
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	15 / 289 (5.19%) 16	14 / 286 (4.90%) 15	3 / 246 (1.22%) 3

Non-serious adverse events	DB ATV+RTV+TVD to OL GEN	DB ATV+RTV+TVD to OL ATV+RTV+TVD	
Total subjects affected by non-serious adverse events subjects affected / exposed	68 / 159 (42.77%)	20 / 53 (37.74%)	
Nervous system disorders Headache			

subjects affected / exposed occurrences (all)	20 / 159 (12.58%) 28	5 / 53 (9.43%) 5	
Neuropathy peripheral subjects affected / exposed occurrences (all)	10 / 159 (6.29%) 14	7 / 53 (13.21%) 7	
Dizziness subjects affected / exposed occurrences (all)	0 / 159 (0.00%) 0	1 / 53 (1.89%) 1	
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	4 / 159 (2.52%) 5	0 / 53 (0.00%) 0	
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	3 / 159 (1.89%) 3	2 / 53 (3.77%) 2	
Gastrointestinal disorders Nausea subjects affected / exposed occurrences (all)	7 / 159 (4.40%) 7	2 / 53 (3.77%) 2	
Vomiting subjects affected / exposed occurrences (all)	4 / 159 (2.52%) 4	0 / 53 (0.00%) 0	
Diarrhoea subjects affected / exposed occurrences (all)	5 / 159 (3.14%) 5	1 / 53 (1.89%) 1	
Dyspepsia subjects affected / exposed occurrences (all)	3 / 159 (1.89%) 3	0 / 53 (0.00%) 0	
Abdominal pain subjects affected / exposed occurrences (all)	3 / 159 (1.89%) 3	2 / 53 (3.77%) 2	
Hepatobiliary disorders Ocular icterus subjects affected / exposed occurrences (all)	0 / 159 (0.00%) 0	0 / 53 (0.00%) 0	

Jaundice subjects affected / exposed occurrences (all)	0 / 159 (0.00%) 0	1 / 53 (1.89%) 1	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	9 / 159 (5.66%) 10	2 / 53 (3.77%) 2	
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all) Arthralgia subjects affected / exposed occurrences (all)	14 / 159 (8.81%) 15 5 / 159 (3.14%) 6	1 / 53 (1.89%) 1 1 / 53 (1.89%) 1	
Infections and infestations Upper respiratory tract infection subjects affected / exposed occurrences (all) Malaria subjects affected / exposed occurrences (all) Urinary tract infection subjects affected / exposed occurrences (all) Influenza subjects affected / exposed occurrences (all) Vulvovaginal candidiasis subjects affected / exposed occurrences (all) Nasopharyngitis subjects affected / exposed occurrences (all)	23 / 159 (14.47%) 30 8 / 159 (5.03%) 9 9 / 159 (5.66%) 9 12 / 159 (7.55%) 19 6 / 159 (3.77%) 8 6 / 159 (3.77%) 7	10 / 53 (18.87%) 12 1 / 53 (1.89%) 1 0 / 53 (0.00%) 0 1 / 53 (1.89%) 1 4 / 53 (7.55%) 6 0 / 53 (0.00%) 0	
Metabolism and nutrition disorders Decreased appetite			

subjects affected / exposed	0 / 159 (0.00%)	1 / 53 (1.89%)	
occurrences (all)	0	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
28 August 2012	<ul style="list-style-type: none">• Updated following Food and Drug Administration (FDA) approval of Stribild• Changed HIV-1 RNA inclusion criteria (from $\geq 1,000$ copies/mL to ≥ 500 copies/mL)• Updated and clarified post-Week 48 visits• Added study sites in Mexico and Russia• Updated study questionnaires• Removed dosing diary requirement for regular study visits (to be administered for intensive pharmacokinetic (PK) substudy only)• Added hair specimen collection PK substudy• Added cervicovaginal fluid (CVF) PK substudy• Updated and clarified intensive PK substudy to intensive oral contraceptive (OC) PK substudy• Added Cystatin C and Urine Chemistry at all visits Baseline through unblinding• Updated demographic and medical history information to be collected at screening visit• Clarified adverse event (AE) and serious adverse event (SAE) reporting through the electronic case report form (eCRF) system• Clarified adverse event (AE) and serious adverse event (SAE) reporting through the electronic case report form (eCRF) system• Added another secondary efficacy endpoint: The proportion of subjects who have virologic failure, using the US FDA-defined snapshot algorithm, at Week 48• Clarified risk-benefit assessment measures provided to Independent Data Monitoring Committee (IDMC)• General formatting/spelling corrections

21 January 2014	<ul style="list-style-type: none"> • Added a 48 week OLE <p>Subjects initially randomized to the STB group (Treatment Group 1) had the option to continue open-label STB at Week 60 (Unblinding Visit/OLE Week 0) for an additional 48 weeks on study as part of an OLE.</p> <p>Subjects initially randomized to the ATV/r+TVD group (Treatment Group 2) had the option to be rerandomized to continue ATV/r+TVD or switch to GEN in a 1:3 randomization at Week 60 for an additional 48 weeks on study as part of an OLE.</p> <ul style="list-style-type: none"> • Additional dual-energy x-ray absorptiometry (DXA) data were obtained in the STB group in the OLE at Week 48. • DXA data in subjects from Treatment Group 2 who elected to continue in the OLE were collected at open-label Weeks 0, 24 and 48. • Added OC PK substudy to assess drug-drug interaction (DDI) between oral hormonal contraceptives and components of study drugs during the OLE in the STB group. This intensive PK study was completed after 7 days of administration of an OC regimen in women receiving open-label STB. • Updated number of sites and list of countries (100 sites/countries included US, Mexico, Puerto Rico, Europe, Russia, Uganda, Dominican Republic, and Thailand) • Added secondary objectives to evaluate the safety, efficacy, and tolerability of STB STR, ATV/r+TVD and GEN STR in the OLE Updated statistical methods to assess the secondary endpoints • Updated background information with new data on STB and provided background on GEN • Updated concomitant medication guidelines to be consistent with current labeling for STB and GEN • Added hepatitis B virus surface antigen test and anti-hepatitis C antibody test at baseline and Week 60 (Unblinding Visit/OLE Week 0) • Updated virologic management guidelines to include retesting window for any virologic rebounds over > 50 copies/mL • Updated safety reporting contact information
-----------------	--

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/27562742>